ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2590

Association Between Frailty and Readmissions in Hospitalized Patients with Systemic Lupus Erythematosus (SLE)

Christopher Leung1, Waqas Tahir2, Yenny Rosli3, Sarah Lieber4, Una Makris5, Radjiv Goulabchand6, Siddharth Singh7 and Namrata Singh8, 1Georgetown University School of Medicine, Washington, DC, 2Mayo Clinic, Jacksonville, FL, 3University of Washington, Seattle, WA, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5UT Southwestern Medical Center and Dallas VA, Dallas, TX, 6University of California San Diego, La Jolla, CA, 7University of California San Diego, San Diego, CA, 8University of Washington, Bellevue, WA

Meeting: ACR Convergence 2023

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 15, 2023

Title: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes IV: Outcomes & Comorbidity

Session Type: Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: SLE has one of the highest 30-day hospital readmission rates among chronic conditions1. Frailty is common2 and associated with hospitalization3 in SLE, but whether frailty is associated with worse outcomes after hospital admission, including readmissions, is unknown. Our objective was to evaluate the association between frailty status and risk of readmissions, inpatient mortality at readmissions, and cost of admission among patients with SLE.

Methods: Using ICD-10 codes, we identified adults >18 years of age within the National Readmissions Database who had a primary or secondary diagnosis of SLE and were hospitalized between January and June 2018. We excluded patients who died during the index hospitalization, had an elective hospitalization, were transferred from another hospital, or were missing length of stay (LOS) or total cost values. Using the validated claims-based Hospital Frailty Risk Score4, we categorized individuals as either frail (score≥5) or non-frail (score<5) at the time of index hospitalization. Age, sex, insurance type, household income, Elixhauser Comorbidity Index (ECI), and LOS were extracted from the dataset. Primary outcome was readmission rates following discharge from the index hospitalization. Secondary outcomes included inpatient mortality, and the economic burden of hospitalizations. We compared baseline characteristics and primary and secondary outcomes between frail and non-frail patients with SLE using descriptive statistics. We used Cox proportional hazard models to estimate the association between frailty and risk of readmissions, after adjustment for relevant covariates.

Results: We identified 39,738 patients with SLE admitted during the study period. Over a median follow-up of 9 months, frail patients with SLE (n = 18,385, 46.3%) were older with Medicare/Medicaid coverage and had higher ECI scores and longer LOS compared to non-frail patients with SLE (n = 21,353, 53.7%) (Table 1). Frail patients with SLE had more prolonged hospitalizations defined by LOS > 7 days with higher costs per hospitalization. Readmission rates in frail patients with SLE were significantly higher. At index hospitalization, frail patients had significantly higher inpatient mortality and fewer days-to-readmission on average (Table 2). In multivariable Cox proportional hazard analysis, frailty was independently associated with a 10% higher risk of readmission after adjustment for covariates (Table 3).

Conclusion: Among patients with SLE who were hospitalized, frailty is associated with more readmissions, higher mortality, and greater economic burden of hospitalization as compared to non-frail SLE patients. Assessing frailty status may help risk stratify patients with SLE at higher risk for readmission. Further research is needed to determine strategies to reduce frailty in patients with SLE in order to decrease readmission rates and other adverse health outcomes.

Supporting image 1

Table 1: Baseline Patient, Hospital, and Hospitalization Characteristics of Patients with SLE at Time of Index Admission by Frailty Status

Supporting image 2

Table 2: Longitudinal Hospitalization-Related Outcomes in Frail and Non-frail Patients with SLE

Supporting image 3

Table 3: Cox Proportional Hazard Analysis Evaluating Risk of Readmission by Frailty Risk Score.


Disclosures: C. Leung: None; W. Tahir: None; Y. Rosli: None; S. Lieber: None; U. Makris: None; R. Goulabchand: None; S. Singh: None; N. Singh: None.

To cite this abstract in AMA style:

Leung C, Tahir W, Rosli Y, Lieber S, Makris U, Goulabchand R, Singh S, Singh N. Association Between Frailty and Readmissions in Hospitalized Patients with Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/association-between-frailty-and-readmissions-in-hospitalized-patients-with-systemic-lupus-erythematosus-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-frailty-and-readmissions-in-hospitalized-patients-with-systemic-lupus-erythematosus-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology